Valneva (Austria)

Recent papers from Valneva (Austria)

1. Imported chikungunya in French travelers returning from outbreak-affected regionsJournal of Travel Medicine · 2026
2. A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individualsNature Communications · 2026
3. Limited tissue persistence confirms attenuation of live-attenuated chikungunya vaccine VLA1553 in non-human primatesnpj Vaccines · 2026
4. Neurological complications of Zika virus and their impact on quality of life: a narrative reviewTropical Medicine and Health · 2026
5. Chikungunya virus-neutralizing antibody persistence four years after single-dose vaccination with VLA1553 (IXCHIQ®)Vaccine · 2026
6. The impact of unspecific viral adsorption on pharmaceutical container surfaces in vaccine process developmentVaccine · 2026
7. Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ)Vaccine · 2026
8. Cytokine-Based Rapid Process Control of Live Virus Production: MCP-1 as a Cross-Family Biomarker in Vero CellsJournal of Virological Methods · 2026
9. Protective properties of a candidate C-terminal domain OspA vaccine for prevention of Lyme diseaseVaccine · 2026
10. Safety of live attenuated vaccines in immunocompromised individuals and pregnant women: a systematic literature reviewExpert Review of Vaccines · 2025
11. Evaluating chikungunya outbreak size and emergency vaccination strategies in Miami: an exploratory modeling studyBMC Public Health · 2025
12. Clinical outcomes of chikungunya across age groups: A systematic reviewSHILAP Revista de lepidopterología · 2025
13. Intestinal inflammation induced by heat-labile toxin-producing enterotoxigenic E: Coli infection and impact on immune responses in an experimental human challenge modelPLoS neglected tropical diseases · 2025
14. Comprehensive Assessment of Reactogenicity and Safety of the Live-Attenuated Chikungunya Vaccine (IXCHIQ®)Vaccines · 2025
15. Assessment of the transmission of live-attenuated chikungunya virus vaccine VLA1553 by Aedes albopictus mosquitoesParasites & Vectors · 2025
16. Assessing chikungunya’s economic burden and impact on health-related quality of life: Two systematic literature reviewsPLoS neglected tropical diseases · 2025
17. Strengthening the EU Health Technology Assessment Regulation: Integrating National Immunization Technical Advisory Groups for Comprehensive Vaccine AssessmentsJournal of Market Access & Health Policy · 2025
18. Intestinal inflammation induced by heat-labile toxin-producing Enterotoxigenic E. Coli infection and impact on immune responses in an experimental human challenge model2025
19. Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineagesEmerging Microbes & Infections · 2025
20. Strategic vaccination responses to Chikungunya outbreaks in Rome: Insights from a dynamic transmission modelPLoS neglected tropical diseases · 2024